Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Serum hepatocyte growth factor and cancer mortality in an apparently healthy Japanese population.

Otsuka M, Adachi H, Jacobs DR Jr, Hirai Y, Enomoto M, Fukami A, Kumagae S, Nanjo Y, Yoshikawa K, Esaki E, Kumagai E, Yokoi K, Ogata K, Tsukagawa E, Kasahara A, Ohbu K, Imaizumi T.

J Epidemiol. 2012;22(5):395-401.

2.

Circulating Inflammatory and Hemostatic Biomarkers are Associated with All-Cause Death and Cancer Death in a Population of Community-Dwelling Japanese: the Tanushimaru Study.

Enomoto M, Adachi H, Fukami A, Yoshimura A, Obuchi A, Nakamura S, Nohara Y, Nakao E, Umeki Y, Hori K, Fukumoto Y.

Clin Med Insights Cardiol. 2015 Apr 13;8(Suppl 3):43-8. doi: 10.4137/CMC.S17065. Review.

3.

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.

Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M.

Int J Cancer. 2009 Oct 1;125(7):1657-62. doi: 10.1002/ijc.24554.

4.

Plasma endothelin-1 level is a predictor of 10-year mortality in a general population: the Tanushimaru study.

Yokoi K, Adachi H, Hirai Y, Enomoto M, Fukami A, Ogata K, Tsukagawa E, Kasahara A, Imaizumi T.

Circ J. 2012;76(12):2779-84.

5.

Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting.

Yuan J, Watanabe M, Suliman M, Qureshi AR, Axelsson J, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2015 Feb;30(2):274-82. doi: 10.1093/ndt/gft265.

PMID:
23975839
6.

Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.

Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML; CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators..

Circulation. 2003 Feb 4;107(4):524-30.

7.

Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the Vitality 90+ study.

Kämppä N, Mäkelä KM, Lyytikäinen LP, Peltonen N, Hautamäki J, Seppälä I, Mononen N, Goebeler S, Karhunen PJ, Hervonen A, Hurme M, Jylhä M, Lehtimäki T.

Exp Gerontol. 2013 Nov;48(11):1167-72. doi: 10.1016/j.exger.2013.07.009.

PMID:
23911532
8.

Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure.

Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, Berger R, Mörtl D, Huber K, Pacher R, Wojta J, Niessner A, Hülsmann M.

Heart. 2011 Jul;97(14):1158-63. doi: 10.1136/hrt.2010.220228.

PMID:
21572126
9.

Independent association of elevated serum hepatocyte growth factor levels with development of insulin resistance in a 10-year prospective study.

Tsukagawa E, Adachi H, Hirai Y, Enomoto M, Fukami A, Ogata K, Kasahara A, Yokoi K, Imaizumi T.

Clin Endocrinol (Oxf). 2013 Jul;79(1):43-8. doi: 10.1111/j.1365-2265.2012.04496.x.

PMID:
22788978
10.

Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.

Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF.

Clin Cancer Res. 2008 Nov 15;14(22):7385-90. doi: 10.1158/1078-0432.CCR-07-5110.

11.

Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma.

Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y.

J Gastroenterol. 2004 Dec;39(12):1182-8.

PMID:
15622483
12.

Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.

Hashem M, Essam T.

J Egypt Natl Canc Inst. 2005 Jun;17(2):114-20.

13.

Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery.

Fang MY, Wang SY, Zheng YB, Gong LY, Bao WL, Gu DL, Mao WM.

Eur Rev Med Pharmacol Sci. 2014;18(3):398-403.

14.

Serum levels of hepatocyte growth factor in patients with breast cancer.

Sheen-Chen SM, Liu YW, Eng HL, Chou FF.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):715-7.

15.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0.

PMID:
24370903
16.

[Relationship and expression of hepatocyte growth factor and vascular endothelial growth factor in serum preoperative and postoperative patients with laryngeal squamous cell cancer].

Wang Y, Zhao H, Chen J, Liu L, Zhang P, Che J, Wang G.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Dec;24(24):1112-5. Chinese.

PMID:
21395178
17.

Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Kim H, Youk J, Yang Y, Kim TY, Min A, Ham HS, Cho S, Lee KH, Keam B, Han SW, Oh DY, Ryu HS, Han W, Park IA, Kim TY, Noh DY, Im SA.

J Cancer Res Clin Oncol. 2016 Mar;142(3):707-14. doi: 10.1007/s00432-015-2072-5.

PMID:
26577828
18.

Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.

Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW.

Eur J Surg Oncol. 2008 Mar;34(3):333-8.

PMID:
17218078
19.

Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ.

Cancer Res. 1997 Feb 1;57(3):433-9.

20.

Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.

Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A.

Blood. 1998 Feb 1;91(3):806-12.

Items per page

Supplemental Content

Support Center